Trial Profile
Ascites Control Treating Ovarian Cancer With Bevacizumab: 'ACT-OB'
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms ACT-OB
- Sponsors Roche
- 11 Jun 2014 New trial record